Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04953000
Other study ID # TAK-761-4001
Secondary ID MACS-2020-051901
Status Completed
Phase
First received
Last updated
Start date August 19, 2021
Est. completion date April 4, 2023

Study information

Verified date July 2023
Source Takeda
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The main aim of this study is to learn about changes in the lowest blood levels of Factor VIII in men and boys when upgraded from standard prophylaxis with Advate to individualized prophylaxis with Advate. No study medicines will be provided to participants in this study. The study sponsor will not be involved in how participants are treated but will provide instructions on how the clinics will record what happens during the study. Participants will need to visit the study doctor 3 times in total during the study. During these visits, study data will be collected by the study doctor.


Description:

Local, Multicenter, Non-interventional, Ambispective Study in Severe Hemophilia A Patients on Standard and PK-tailored Prophylaxis With Octocog Alfa (AdvateĀ®) in the Russian Federation


Recruitment information / eligibility

Status Completed
Enrollment 94
Est. completion date April 4, 2023
Est. primary completion date April 4, 2023
Accepts healthy volunteers No
Gender Male
Age group N/A and older
Eligibility Inclusion Criteria: - Male participants of all ages with severe hemophilia A (FVIII ?1%) or moderate hemophilia A with severe bleeding phenotype who: - had been on standard prophylaxis or PK-tailored prophylaxis with octocog alfa during at least 12 months prior to the study enrollment (150 participants) or who started AdvateĀ® treatment in 2021 (20 participants), - is being treated with octocog alfa at the moment of enrolment with any of the above mentioned treatment modalities, and - had been assigned octocog alfa provision in Federal reimbursement program 2021 - Availability of participants' records sufficient for data collection according to the study objectives during the retrospective period of the study for participants who had been on standard prophylaxis or PK-tailored prophylaxis with octocog alfa during at least 12 months prior to the study enrollment - Written informed consent provided by the participant or, in case of children below 14 years of age, by participant's parent or participant's legally acceptable representative. Exclusion Criteria: - Failure to obtain the participant's written informed consent - Participation in any interventional study of products for hemophilia or other hemostasis disturbances treatment during 12 months prior to the study enrollment for participants who has retrospective data collection period and during 12 months after the study enrollment for all participants.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Russian Federation Chelyabinsk Regional Children's Clinical Hospital Chelyabinsk
Russian Federation City Children's Hospital No. 1 Kazan Tatarstan
Russian Federation Children's Regional Clinical Hospital Khabarovsk
Russian Federation Krasnoyarsk Regional Clinical Center for Maternal and Child Health Krasnoyarsk
Russian Federation Morozovskaya Children's City Clinical Hospital of the Department of Healthcare of the city of Moscow Moscow
Russian Federation State Budgetary Institution of Healthcare "Republican children's clinical hospital" of the Ministry of Health of the Kabardino-Balkar Republic Nalchik
Russian Federation State Novosibirsk Regional Clinical Hospital Novosibirsk
Russian Federation Regional Children's Clinical Hospital Rostov-on-Don
Russian Federation City Polyclinic No. 37 St. Petersburg
Russian Federation Regional Children's Clinical Hospital No. 1 Vladivostok
Russian Federation Volgograd Regional Clinical Oncological Dispensary Volgograd
Russian Federation Voronezh Regional Children's Clinical Hospital No. 1 Voronezh
Russian Federation State Autonomous Healthcare Institution of the Sverdlovsk Region "Regional Children's Clinical Hospital" Yekaterinburg

Sponsors (1)

Lead Sponsor Collaborator
Takeda

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time per Week Spent With Factor VIII (FVIII) Trough Level Below 1 Percent (%) on the Standard Prophylaxis and After Pharmacokinetic (PK) -tailored Prophylaxis PK-tailoring prophylaxis is defined as FVIII replacement prophylactic therapy based on PK parameters of each particular participant. Time per week spent with Through FVIII level below 1% on standard and PK-tailored prophylaxis will be reported. From 12 months prior to study enrollment up to Visit 3 (Month 12)
Secondary Percentage of Participants With More Than 19 Hours per Week Spent With FVIII Trough Level Below 1% on Standard Prophylaxis Versus on PK-tailored Prophylaxis Percentage of participants with more than 19 hours per week with FVIII trough level below 1% on standard and PK-tailored prophylaxis will be reported. From 12 months prior to study enrollment up to Visit 3 (Month 12)
Secondary Percentage of Participants With Upgraded Dosing Regimen Based on PK-assessment Upgraded dosing regimen includes dose upgrade, dosing intervals modification, and/or FVIII trough level upgrade to above 1%. Percentage of participants with upgraded dosing regimen based on PK-assessment will be reported. Baseline up to Visit 3 (Month 12)
Secondary Percentage of Time per Week Spent With FVIII Trough Level Below 1%, 1 to less than (<) 3%, and Greater Than or Equal to (>=) 3% While on Standard and Individualized Prophylaxis Individualized prophylaxis is defined as prophylactic therapy based on PK parameters of each individual participant. Percentage of time per week spent with FVIII through level below 1%, 1- <3%, and >=3% while on standard and individualized prophylaxis will be reported. From 12 months prior to study enrollment up to Visit 3 (Month 12)
Secondary Percentage of Participants With FVIII Trough Level Permanently Above 1% on Standard Prophylaxis vs on PK-tailored Prophylaxis Percentage of participants with FVIII trough level permanently above 1% on standard and PK-tailored prophylaxis will be reported. From 12 months prior to study enrollment up to Visit 3 (Month 12)
Secondary Correlation Between the Time per Week Spent With FVIII Trough Level Below 1% and Spontaneous Annualized Bleeding Rate (ABR) on Standard Prophylaxis Correlation between the time per week spent with FVIII trough level below 1% and spontaneous ABR on standard prophylaxis will be assessed using Pearson's correlation coefficient. From 12 months prior to study enrollment up to Visit 3 (Month 12)
Secondary Correlation Between the Time per Week Spent With FVIII Trough Level Below 1% and Spontaneous Annualized Joint Bleeding Rate (AJBR) on Standard Prophylaxis Correlation between the time per week spent with FVIII trough level below 1% and spontaneous AJBR on standard prophylaxis will be assessed using Pearson's correlation coefficient. From 12 months prior to study enrollment up to Visit 3 (Month 12)
Secondary Total Consumption of FVIII Before and After PK-tailored Prophylaxis in Participants With Upgraded Dosing Regimen Total consumption of FVIII before and after PK-tailored prophylaxis in participants with upgraded dosing regimen will be reported. From 12 months prior to study enrollment up to Visit 3 (Month 12)
Secondary Percentage of Participants With Positive Dynamics of Body Status After Transfer From Standard to Individualized Prophylaxis Positive dynamics of body status is related with increased physical activity (change in body mass index [BMI], waist: hip ratio [WHR]. Percentage of participants with positive dynamics of body status after transfer from standard to individualized prophylaxis will be reported. Baseline up to Visit 3 (Month 12)
Secondary Percentage of Participants Categorized Based on Number of Hospitalizations due to Insufficient Bleeding Control Before and After PK-tailored Prophylaxis Percentage of participants categorized based on number of hospitalization due to insufficient bleeding control before and after PK-tailored Prophylaxis will be reported. From 12 months prior to study enrollment up to Visit 3 (Month 12)
Secondary Percentage of Participants Categorized Based on Number of Days Away From Work and School/Institute Due to Insufficient Bleeding Control Before and After PK-tailored Prophylaxis Percentage of participants categorized based on number of days away from work and school/institute due to insufficient bleeding control before and after PK-tailored prophylaxis will be reported. From 12 months prior to study enrollment up to Visit 3 (Month 12)
See also
  Status Clinical Trial Phase
Completed NCT03834727 - Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders
Completed NCT03191799 - A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors Phase 3
Completed NCT01599819 - BAX 855 Dose-Escalation Safety Study Phase 1
Terminated NCT04541628 - Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A Phase 1/Phase 2
Completed NCT02847637 - A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors Phase 3
Completed NCT04072237 - Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia Phase 1
Completed NCT04085458 - Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation) Phase 4
Completed NCT04565236 - A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A Phase 4
Recruiting NCT05987449 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A Phase 1/Phase 2
Active, not recruiting NCT04621916 - Preventing Inhibitor Recurrence Indefinitely Phase 4
Not yet recruiting NCT02888223 - Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A Phase 1
Completed NCT02528968 - National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A N/A
Completed NCT02225483 - Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function N/A
Completed NCT02199717 - An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia N/A
Completed NCT01217255 - Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World
Terminated NCT00995046 - Individually Tailored Prophylaxis in Patients With Severe Hemophilia A N/A
Completed NCT00969319 - Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America N/A
Completed NCT00868530 - Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects Phase 3
Completed NCT00839202 - Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay N/A
Completed NCT00629837 - Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980 Phase 1